A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors

Clinical Cancer Research

Volumn 9, Issue 2, 2003, Pages 633-640

  Santana, Victor M ^a,b   Zamboni, William C ^a   Kirstein, Mark N ^a   Tan, Ming ^a   Liu, Tiebin ^a   Gajjar, Amar ^a,b   Houghton, Peter J ^a,b   Stewart, Clinton F ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; LOMUSTINE; PACLITAXEL; PREDNISONE; PROCARBAZINE; THIOTEPA; TOPOTECAN;

ADOLESCENT; ADULT; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DIARRHEA; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EXPOSURE; DRUG MECHANISM; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; MALE; NEUTROPENIA; NEUTROPHIL; PILOT STUDY; PRIORITY JOURNAL; RASH; RECURRENT CANCER; SOLID TUMOR; STANDARD; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADOLESCENT; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CONFIDENCE INTERVALS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; NEOPLASMS; PILOT PROJECTS; TOPOTECAN;

EID: 0037316914     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Furman, W. L., Stewart, C. F., Kirstein, M., Kepner, J. L., Bernstein, M. L., Kung, F., Vietti, T. J., Steuber, C. P., Becton, D. L., Baruchel, S., and Pratt, C. Protracted intermittent schedule of topotecan in children with refractory acute leukemia: a pediatric oncology group study. J. Clin. Oncol., 20: 1617-1624, 2002.
2. Houghton, P. J., Chesire, P. J., Myers, L., Stewart, C. F., Synold, T. W., and Houghton, J. A. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother. Pharmacol., 31: 229-239, 1992.
3. Pratt, C. B., Stewart, C. F., Santana, V. M., Bowman, L., Furman, W., Ochs, J., Marina, N., Kuttesch, J. F., Heideman, R., Sandlund, J. T., Avery, L., and Meyer, W. H. Phase I study of topotecan for pediatric patients with malignant solid tumors. J. Clin. Oncol., 12: 539-543, 1994.
4. Tubergen, D. G., Stewart, C. F., Pratt, C. B., Zamboni, W. C., Winick, N., Santana, V. M., Dryer, Z. A., Kurtzberg, J., Bell, B., Grier, H., and Vietti, T. J. Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: A Pediatric Oncology Group Study. J. Pediatr. Hematol. Oncol., 18: 352-361, 1996.
5. Houghton, P. J., Cheshire, P. J., Hallman, J. D., Lutz, L., Friedman, H. S., Danks, M. K., and Houghton, J. A. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother. Pharmacol., 36: 393-403, 1995.
6. Zamboni, W. C., Stewart, C. F., Thompson, J., Santana, V. M., Cheshire, P. J., Richmond, L. B., Xiaolong, L., Poquette, C., Houghton, J. A., and Houghton, P. J. Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts. J. Natl. Cancer Inst. (Bethesda), 90, 505-511, 1998.
7. Furman, W. L., Baker, S. D., Pratt, C. B., Rivera, G., Evans, W. E., and Stewart, C. F. Escalating systemic exposure to topotecan following a 120-hr continuous infusion in children with relapsed acute leukemia. J. Clin. Oncol., 14: 1504-1511, 1996.
8. Stewart, C. F., Baker, S. D., Heideman, R. L., Jones, D., Crom, W. R., and Pratt, C. B. Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity. J. Clin. Oncol., 12: 1946-1954, 1994.
9. van Warmerdam, L. J., Verweij, J., Schellens, J. H., Rosing, H., Davies, B. E., de Boer-Dennert, M., Maes, R. A., and Beijnen, J. H. Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks. Cancer Chemother. Pharmacol., 35: 237-245, 1995.
10. Zamboni, W. C., Bowman, L. C., Tan, M., Santana, V. M., Houghton, P. J., Meyer, W. H., Pratt, C. B., Heideman, R. L., Gajjar, A. J., Pappo, A. S., and Stewart, C. F. Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors. Cancer Chemother. Pharmacol., 43: 454-460, 1999.
11. Zamboni, W. C., Gajjar, A. J., Heideman, R. L., Beijnen, J. H., Rosing, H., Houghton, P. J., and Stewart, C. F. Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. Clin. Cancer Res., 4: 783-789, 1998.
12. D'Argenio, D. Z., and Schumitzky, A. A program package for simulation and parameter estimation in pharmacokinetic systems. Comput. Programs Biomed., 9: 115-134, 1979.
13. Gibaldi, M., and Perrier, D. (eds.). Pharmacokinetics. New York: Marcel Dekker, 1982.
14. Stewart, C. F., Liu, C. Y., Zamboni, W. C., Ma, M. K., Kirstein, M. N., Hanna, S. K., Gajjar, A. J., Santana, V. M., Houghton, P. J., and Sambol, N. C. Population pharmacokinetics of topotecan in children and adolescents. Proc. Am. Soc. Clin. Oncol., 19: 177a, 2000.
15. Gallo, J. M., Laub, P. B., Rowinsky, E. K., Grochow, L. B., and Baker, S. D. Population pharmacokinetic model for topotecan derived from phase I clinical trials. J. Clin. Oncol., 18: 2459-2467, 2000.
16. Shiffiett, S. L., McCune, J. S., Faucette, S. R., Donahue, A. E., Gillenwater, H. H., Ma, M., Kirstein, M. N., Socinski, M. A., Stewart, C. F., and Lindley C. Therapeutic drug monitoring (TDM) for topotecan (T) in combination with carboplatin (P) and etoposide (E) for extensive stage small cell lung cancer. Proc. Am. Soc. Clin. Oncol., 19: 188a, 2000.
17. Montazeri, A., Boucaud, M., Lokiec, F., Pinguet, F., Culine, S., Deporte-Fety, R., Albin, N., Laguerre, B., Goupil, A., Bugat, R., Canal, P., and Chatelut, E. Population pharmacokinetics of topotecan: intraindividual variability in total drug. Cancer Chemother. Pharmacol., 46: 375-381, 2000.
18. Zamboni, W. C., Houghton, P. J., Johnson, R. K., Hulstein, J. L., Crom, W. R., Cheshire, P. J., Hanna, S. K., Richmond, L. B., Luo, X., and Stewart, C. F. Probenecid alters topotecan systemic and renal disposition by inhibiting renal tubular secretion. J. Pharmacol. Exp. Ther., 284: 89-94, 1998.
19. Nitschke, R., Parkhurst, J., Sullivan, J., Harris, M. B., Bernstein, M., and Pratt, C. Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study. J. Pediatr. Hematol. Oncol., 20: 315-318, 1998.
20. Zamboni, W. C., Gajjar, A. J., Mandrell, T. D., Einhaus, S. L., Danks, M. K., Rogers, W. P., Heideman, R. L., Houghton, P. J., and Stewart, C. F. A four-hour topotecan infusion achieves cytotoxic exposure throughout the neuraxis in the nonhuman primate model: implications for treatment of children with metastatic medulloblastoma. Clin. Cancer Res., 4: 2537-2544, 1998.